Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients

NCT00718341 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Fragile X Syndrome

Interventions

DRUG: AF056
DRUG: Placebo

Sponsor

Novartis